

CURRICULUM VITAE

MATTHEW F. KOHLER, M.D., FACOG

Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Medical University of South Carolina
96 Jonathan Lucas Street, Suite 634
P.O. Box 250619
Charleston, SC 29425-2233

Telephone (843) 792-8176 (Louise)
Fax: (843) 792-0533

EDUCATION

Fellowship, Gynecologic Oncology
Duke University
Durham, NC
1991-1994

Residency, Obstetrics and Gynecology
Duke University
Durham, NC
1987-1991

Medical School, Doctor of Medicine
Duke University
Durham, NC
1983-1987

Undergraduate, BA, Biochemistry
Yale University
New Haven, CT
1979-1983
Magna Cum Laude
Distinction in the Major

MEDICAL LICENSURE

| | |
|----------------|----------------|
| California | 1994 - Present |
| North Carolina | 1988 - Present |
| South Carolina | 1998 - Present |

BOARD CERTIFICATION

Board Certified: American Board Obstetrics and Gynecology - 11/95, recertified 2005, 2006, 2007

Board Certified: Gynecologic Oncology - 4/97, recertified 2005, 2006, 2007

ACADEMIC APPOINTMENTS

3/98 - Present Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Medical University of South Carolina
Charleston, SC

9/94-2/98 Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
UCI College of Medicine
Irvine, CA

7/91-9/94 Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Duke University Medical Center
Durham, NC

NON-ACADEMIC APPOINTMENTS

1998 - 2004 Clinical Staff
Veteran's Medical Center
Charleston, South Carolina

PROFESSIONAL ACTIVITY

Awards and Honors

2007 ACOG Leadership Institute Chapel Hill, NC

2006 Nurse Alliance Leadership Council "Monthly Magnetic MD Award"

2006 America's Top Doctors for Cancer

| | |
|------------------|---|
| 2005 | ACOG National Faculty Award for Resident Teaching |
| 2003 | Best Doctors in America |
| 2003 | Nominated for Golden Apple Award, MUSC |
| 2002 | Nominated for Golden Apple Teaching Award, MUSC |
| 4/02 | Named in "Top Doctors For Women", Ladies' Home Journal |
| 2001 | Nominated for Health Science Foundation Teaching Excellence Award, MUSC |
| 6/94 | Distinguished Faculty Fellow Award Department of Obstetrics and Gynecology Duke University |
| 1/94 | Elected to Alpha Omega Alpha |
| 3/93 | Foundation Prize (first place) Society of Gynecologic Oncologists "Clonal origin of ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation and X-chromosome inactivation" Palm Desert, CA |
| 7/91 and 7/92 | Seelinger Award in Cancer Research Duke Comprehensive Cancer Center |
| 6/90 | "Bronze Sucker" Award for surgical excellence, Department of Obstetrics and Gynecology. Duke University |

Contracts, Grants and Research Awards

Sanofi-Aventis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm
Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2
Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic
Malignant Ascites

Matthew F. Kohler, M.D.

Co-principal investigator @MUSC

2007 to present

Sanofi-Aventis

A Multicenter, Randomized, Double-Blind, Parallel-Arm, Two-Stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients with Platinum-Resistant and Topotecan-and/or Liposomal Doxorubicin-Resistant Advanced Ovarian Cancer

Matthew F. Kohler, M.D.

Co-principal investigator @MUSC

2007 to present

Unrestricted gift of \$50,000 to Hollings Cancer Center by patient in 2003

Eli Lilly

A randomized phase III trial of Gemzar versus Doxil with crossover treatment option for patients with platinum-refractory ovarian, fallopian tube or primary peritoneal cancer undergoing 2nd or 3rd line chemotherapy

Matthew F. Kohler, M.D.

\$24,500

November 2002 to present

Aventis

A multicenter, randomized, phase III comparative study to compare the efficacy and safety of Taxotere/carboplatin combination therapy versus sequential therapy with Taxotere then carboplatin as 2nd line treatment of patients with relapsed, platinum-sensitive ovarian cancer.

Matthew F. Kohler, M.D.

\$49,500

January 2004 to present

GOG Grant

Co-principal investigator at MUSC

Contracts, Grants and Research Awards (cont'd)

Faculty Career Development Award

Molecular Detection of Occult Residual Disease in Ovarian Cancer

Matthew F. Kohler, M.D.

\$3,000

1995-1996

American Cancer Society

Clinical Oncology Career Development Award

Molecular genetic analysis of the estrogen receptor gene in endometrial carcinoma"

Matthew Kohler, M.D.

\$90,000

3/95-3/98

Gynecologic Oncology Group Competitive Basic Science Grant
Matthew Kohler M.D. and Andrew Berchuck M.D.
\$15,000
12/92-12/93

Invited Presentations

California Polytechnics, Pomona University, Department of Biology of Cancer, "Gynecologic Malignancies", Pomona, CA, Apr 1995.

University of California Irvine, Department of Biology of Cancer, "Gynecologic Malignancies", Irvine, CA, Mar 1995.

Family Health Plan, Department of Obstetrics and Gynecology, Tumor Board Conference, "Management of Ovarian Germ Cell Tumors", Fountain Valley, CA, Feb 1995.

Fountain Valley Regional Hospital, Department Obstetrics and Gynecology, Tumor Board Conference, "Management of Adnexal Mass in Pregnancy", Fountain Valley, CA, Oct 1994.

Family Health Plan, Department of Obstetrics and Gynecology, Tumor Board Conference, "Management of Adnexal Mass in Pregnancy", Fountain Valley, CA, Oct 1994.

Department Presentations

UCI Medical Center, Department of Obstetrics and Gynecology, Student Lecture Series, "Management of Abnormal Pap Smear", Orange, CA, Nov 1994.

Presentations at Professional Meetings

Discussant, Society of Gynecologic Oncologists Annual Meeting, "Lymph Node Metastases and Prognosis in Patients with Stage IA₂ Cervical Cancer", New Orleans, LA, Feb 1995.

Long Beach Obstetrics & Gynecologic Society Meeting, "Molar Pregnancy and Gestational Trophoblastic Disease", Long Beach, CA, Mar 1995.

Seventeenth Annual Orange County Ob/Gyn Congress, "Management of adnexal mass in pregnancy", Irvine, CA, Apr 1995.

Seventeenth Annual Orange County Ob/Gyn Congress, "Management of pelvic hemorrhage", Irvine, CA, Apr 1995.

Service as Reviewer of Manuscripts

Ad Hoc reviewer, International Journal of Cancer
Ad Hoc reviewer, Obstetrics and Gynecology
Ad Hoc reviewer, American Journal of Obstetrics and Gynecology
Ad Hoc reviewer, Cancer
Ad Hoc reviewer, Gynecologic Oncology

Membership in Professional Organizations

Society of Gynecologic Oncologists
Alpha Omega Alpha
American College of Obstetrics and Gynecology
Bayard Carter Society
Thegos Society

Service as Board Examiner

Examiner, General Oral Board Exam, American Board of Obstetrics and Gynecology
2002, 2003

UNIVERSITY AND PUBLIC SERVICE

Hospital - Medical University of South Carolina

Member, Hollings Cancer Center
Member, Cancer Program Committee 2001-Present
Member, Dept. OB/Gyn Clinical Practice Committee

Hospital - UCI Medical Center and Affiliates

Director, Clinical Investigation Shared Resource Committee, 1996
Member, Nutritional Support Committee, 1996
Member, Operating Room Committee, 1995
Member, Cancer Committee, 1995
Member, Human Subjects Review Committee, 1995-

Community

Expert Consultant, Medical Board of California
Vice Chairman, Fountain Valley Regional Hospital and Medical Center Cancer Committee

PUBLICATIONS

Book Chapters, peer reviewed

1. Berchuck A, **Kohler MF**, Bast RC. Molecular genetic features of ovarian carcinoma. In: Huff J, Boyd J, Barrett CJ, eds. Cellular and Molecular Mechanisms of Hormonal Carcinogenesis: Environmental Influences. Wiley-Liss, Inc., 1995.
2. Clarke-Pearson DL, **Kohler MF**, Hurteau JA, Elbendary A. Surgery for advanced ovarian cancer, In: Pitkin RM, Scott JR, eds. Clinical Obstetrics and Gynecology, Hagerstown: JB Lippincott, 1994.
3. **Kohler MF**, DiSaia PJ. Cervical Carcinoma. In: Quilligan EJ, Zuspan FP, eds. Current Therapy in Obstetrics and Gynecology, Fifth edition. WB Saunders, 1998.
4. **Kohler MF**, Soper JT, Gestational Trophoblastic Disease In Gilstrap LC, Cunningham F G and VanDorsten JP, eds. Operative Obstetrics, Second Edition McGraw Hill 2002

Journal Articles, peer reviewed

1. Frommel TO, **Kohler MF**, Balber AE. Trypanosoma brucei brucei and Trypanosoma brucei gambiense: stage-specific differences in wheat germ agglutinin binding and endoglycosidase H sensitivity of glycoprotein oligosaccharides. Exp Parasitol 64: 104, 1987.
2. **Kohler MF**, Berchuck A, Baker ME, Szpak CA, Soper JT, Clarke-Pearson DL. Computed tomography-guided fine-needle aspiration of retroperitoneal lymph nodes in gynecologic oncology. Obstet Gynecol 76: 612-616, 1990.
3. **Kohler MF**, Soper JT, Tucker A, Clarke-Pearson DL. Isolated incisional metastases after intraperitoneal radioactive chromic phosphate therapy for ovarian carcinoma. Cancer 68:1380-1383, 1991.
4. Timmons MC, **Kohler MF**, Addison A. Thumbtack use for control of presacral bleeding and description of instrument for thumbtack application. Obstet Gynecol 78:313-316, 1991.

5. **Kohler MF**, Berchuck A, Davidoff A, Humphrey PA, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC, Marks JR. Overexpression and mutation of p53 in endometrial carcinoma. *Cancer Res* 52:1622-1627, 1992.
6. Kerns BJ, Jordon PA, Moore MB, Humphrey PA, Berchuck A, **Kohler MF**, Bast RC, Iglehart JD, Marks JR. P53 Overexpression in formalin-fixed, paraffin embedded tissue detected by immunohistochemistry. *J. Histochem Cytochem* 40:1047-1051, 1992.
7. Ignar-Trowbridge D, Risinger JT, Dent G, **Kohler MF**, Berchuck A, McLachlan JA, Boyd J. Mutations of the Ki-ras oncogene in endometrial carcinoma. *Obstet Gynecol* 167:227-232, 1992.
8. **Kohler MF**, Kerns BJ, Humphrey PA, Marks JR, Bast RC, Berchuck A. P53 overexpression and mutation in early stage epithelial ovarian cancer. *Obstet Gynecol* 81:643-650, 1993.
9. Jacobs I, **Kohler MF**, Wiseman R, Kerns BJ, Berchuck A, Bast RC. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. *J Natl Cancer Inst* 84:1793-1798, 1992.
10. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal GP, Parker SL, **Kohler MF**, Berchuck A, Boyd J. Mutation of the Ki-ras proto-oncogene in human endometrial hyperplasia and carcinoma. *Cancer Res* 53:1906-1910, 1993.
11. **Kohler MF**, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC Jr., Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. *J Natl Cancer Inst* 85:1513-1519, 1993.
12. **Kohler MF**, Nishii H, Humphrey PA, Sasaki H, Marks JR, Bast RC Jr, Clarke-Pearson DL, Boyd J, Berchuck A. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasia. *Am J Obstet Gynecol* 169:690-694, 1993.
13. Jordan PA, Kerns BJ, Kamel A, Whitaker RS, Pence JC, **Kohler MF**, Bast RC, Kinney RB, Berchuck A. Determination of proliferation index in advanced ovarian carcinoma using quantitative image analysis. *Am J Clin Path* 99:736-740, 1993.
14. Risinger JI, Berchuck A, **Kohler MF**, Watson P, Lynch HT, Boyd J. Genetic Instability of microsatellites in endometrial carcinoma. *Cancer Res* 53:1-4, 1993.

15. Berchuck A, **Kohler MF**, Boente MP, Rodriguez GC, Whitaker RS, Bast RC Jr. Growth regulation and transformation of ovarian epithelium. *Cancer* 71(2):545-551, 1993.
16. Bast RC Jr., Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, **Kohler MF**, Berchuck A. Cell growth regulation in epithelial ovarian cancer. *Cancer* 71(4):1597-1601, 1993.
17. Liu FS, **Kohler MF**, Marks JR, Bast RC Jr, Boyd J, Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. *Obstet and Gynecol* 83:118-124, 1994.
18. Berchuck A, **Kohler MF**, Marks JR, Wiseman R, Boyd J, Bast RC Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. *Am J Obstet Gynecol* 170:246-252, 1994.
19. Berchuck A, **Kohler MF**, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC Jr. Overexpression of p53 is not a feature of benign and early stage borderline epithelial ovarian tumors. *Gynecol Oncol* 52:232-234, 1994.
20. Lukes A, **Kohler MF**, Pieper CF, Kerns BJ, Vick W, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC, Berchuck A. Multivariate analysis of DNA ploidy, p53 and HER-2/neu as prognostic factors in endometrial cancer. *Cancer*, 73(9):2380-2385, 1994.
21. Risinger JI, Berchuck A, **Kohler MF**, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. *Nature Genet* 7(1):98-102, 1994.
22. Fujino T, Risinger JI, Collins NK, Liu F, Nishii H, Takahashi H, Barrett JC, Sasaki H, **Kohler MF**, Berchuck A, Boyd J. Allelotype of endometrial carcinoma. *Cancer Res* 54:4294-4298, 1994.
23. Walmer DK, Padin CJ, Wrona MA, Healy BE, Bentley RC, Tsao MS, **Kohler MF**, McLachlan JA, Gray, KD. Malignant transformation of the human endometrium is associated with overexpression of lactoferrin messenger RNA and protein. *Cancer Res* 55:1-8, 1995.
24. Cliby WA, Clarke-Pearson DL, Dodge R, **Kohler MF**, Rodriguez G, Olt GJ, Soper JT, Berchuck A, Soisson AP. Acute morbidity and mortality associated with selective pelvic and para-aortic lymphadenectomy in the surgical staging of endometrial adenocarcinoma. *J Gynecol Tech* 1(1):19-26, 1995.
25. Lessey BA, Albelda S, Buck CA, Castelbaum AJ, Yeh I, **Kohler MF**, Berchuck A. Distribution of integrin cell adhesion molecules in endometrial cancer. *Am J Pathol* 146(3):717-726, 1995.

26. **Kohler MF**, Berkholz A, Elbendary A, Boyd J, Bast RC Jr, Berchuck A. Mutational analysis of the estrogen receptor gene in endometrial carcinoma. *Obstet Gynecol* 86(1):33-37, 1995.
27. Bast RC, Boyer CM, Xu FJ, Wu S, Wiener JR, **Kohler MF**, O'Brian K, De Sombre K, Dean S, Daley L and Berchuck A. Selected molecular targets for diagnosis and therapy of epithelial ovarian cancer. *Cancer Molec Biol* 1:87-93, 1994.
28. Berchuck A, **Kohler MF**, Bast RC, Jr. Molecular genetic features of ovarian cancer. *Prog Clin BIO Res* 394:269-84, 1996
29. **Kohler MF**, Carney P, Dodge R, Soper Jt, Rodriguez GC, Clarke-Pearson DL, Marks Jr, Berchuck A. P53 overexpression in advanced stage endometrial carcinoma. *Am J Obstet Gynecol* 175(5): 1246-1252, 1996
30. Boente MP, Hamilton TC, Godwin AK, Buetow K, **Kohler MF**, Hogan WM, Berchuck A, Young RC. Early ovarian cancer: A review of HS genetic and biologic factors, detection and treatment. *Current Problems in Cancer* 20(2):83-137, 1996.
31. Tewari K, Cappuccini F, Gambino A, **Kohler MF**, Pewrelli S, DiSaia P. Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy. *Cancer* 82 (8): 1529-1534, 1998
32. Tewari K, Rose GS, Balderston KD, Parto M and **Kohler MF**. Fertility drugs and malignant germ cell tumor of the ovary in pregnancy. *The Lancet* 351: 957-8, 1998
33. Tewari K, Cappuccini F, Rosen RB, Rosenthal J, Asrat T and **Kohler MF**. Relapse of acute lymphoblastic leukemia in pregnancy: Survival following chemoradiation and autologous transfer of interleukin-2 activated stem cells. *Gynecol Oncol* 1999 Jul;74(1):143-6.
34. Tewari K, Cappuccini F, Brewster WR, DiSaia PJ, Berman ML, Manetta A, Syed AMN and **Kohler MF**. Interstitial brachytherapy for vaginal vault recurrences of endometrial cancer. *Gynecol Oncol* 1999 Sep;74(3):416-22.
35. Cloven NG, Manetta A, Berman ML, **Kohler MF** and DiSaia PJ. Management of ovarian cancer in patients older than 80 years of age. *Gynecol Oncol* 73: 137-139, 1999.
36. Tewari K, Cappuccini F, DiSaia PJ, Berman ML, Manetta A and **Kohler MF**. Malignant germ cell tumors of the ovary. *Obstet Gynecol* 95(1):28-33,2000.

37. Yamada SD, Burger RA, Brewster WR, Anton D, **Kohler MF**, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. *Cancer* 2000 Jun 15;88(12):2782-6.
38. Gillette-Cloven N, Burger RA, Monk BJ, McMeekin DS, Vasilev S, DiSaia PJ, **Kohler MF**. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. *Am Coll Surg* 2001 Dec;93(6):626-32.
39. Mathur SP, Mathur RS, Underwood PB, **Kohler MF**, Creasman WT. Circulating levels of insulin-like growth factor-II and IGF binding protein 3 in cervical cancer. *Gynecol Oncol* 2003;91:486-93
40. Creasman WT, **Kohler MF**. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? *Gynecol Oncol* 2004;92:525-9
41. Creasman WT, **Kohler MF**, Odicino F et al. Prognosis of papillary serous clear cell and grade 3 Stage I carcinoma of the endometrium. *Gynecol Oncol* 2004 95(3); 593-6
42. Mathur SP, Mathur RS, Creasman WT, Underwood PB, **Kohler MF**. Early noninvasive diagnosis of cervical cancer: beyond Papsmearrs and HPV testing. *Cancer Biomark* 2005; 1 (2-3) 183-91.
43. Mathur, SP, Mathur RS, Underwood PB, **Kohler MF**, Creasman WT. Circulating levels of insulin-like growth factor-II and IGF binding protein 3 in cervical cancer. *Gynecol Oncol* 2003;91:486-93.
44. Mathur SP, Mathur RE, Creasman WT, Underwood P and **Kohler, M**. Early diagnosis of cervical cancer: Beyond HPV testing. *Disease Markers* 2005;21;1-9.
45. Mathur SP, Mathur RS, Gray EA, Lane D, Underwood P, **Kohler, M**, Creasman WT. Serum vascular endothelial growth factor C(VEGF-C) as a specific biomarker for advanced cervical cancer. Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and BEGF-B. (Journal Article) *Gynecologic Oncology*. 98(3):467-83, 2005 Sep.
46. Guo H, Keefe KA, **Kohler MF**, Chan JK, Juvenile granulose cell tumor of the ovary associated with tuberons sclerosis. *Gynecol Onc* 2006; 102 (1) 118-20.
47. Sapp H, Goetzl L, Creasman WT, **Kohler MF**, Underwood PB, and Esnaola N. Combined adverse effect of African-american race and deep stromal invasion on survival following radical hysterectomy for cervical cancer. *Am J Obstet Gynecol*, in press

48. **Kohler MF** and Creasman WT. Controversies surrounding lymphadenectomy and postoperative radiotherapy in the treatment of carcinoma of the endometrium. *Future Oncology*. 2008; 4(3): 379-87
49. **Kohler MF**, Creasman WT, McCammon RJ, Kavanagh BD, Segreti EM, Boardman Wheelock J and Clawser R. *Emedicine*, 2008, in press

Journal Articles, Other (Includes non-peer review)

1. **Kohler MF**, Berchuck A. Recent advances in the treatment of ovarian germ cell tumors. *Postgrad Obstet Gynecol* 11(21):1-8, 1991.
2. **Kohler MF**, Clarke-Pearson, DL. Fine-needle aspiration in gynecologic oncology. *Clin Obstet Gynecol* 35(1):73-88, 1992.
3. Berchuck A, **Kohler MF**, Bast RC. Oncogenes in ovarian cancer. *Hematol Oncol Clin N Am* 6:813-827, 1992.
4. **Kohler MF**. The adnexal mass in pregnancy. *Postgrad Obstet Gynecol* 14(12):1-6, 1994.
5. Creasman WT, **Kohler MF**. *Adenocarcinoma of the Endometrium*. Royal College of Obstetrics and Gynecology, 1998.

Abstracts and Posters and Other Conference Proceedings

1. Kohler MF, Berchuck A, Clarke-Pearson DL. "Computed tomography-guided fine-needle aspiration of retroperitoneal lymph nodes in gynecologic oncology." Mid Atlantic Gynecologic Oncology Society Wilmington NC, Oct 1990.
2. Clarke-Pearson DL, Cliby WA, Dodge R, Kohler MF, Rodriguez G, Olt G, Soper JT, Berchuck A, Soisson AP. "Morbidity and mortality associated with selective pelvic and para-aortic lymphadenectomy in the surgical staging of endometrial adenocarcinoma." Society of Gynecologic Oncologists, Orlando, FL, Feb 1991.
3. Kohler MF, Soper JT, and Clarke-Pearson DL. "Surgical management of recurrent endometrial carcinoma in the vaginal vault." Mid Atlantic Gynecologic Oncology Society, Ocean City, MD, Oct 1991.
4. Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS Bast RC, Jr. "The role of peptide growth factors and oncogenes in ovarian cancer." NIH

- conference: "perspectives on ovarian cancer in older-age women". Bethesda, MD, Nov 1991.
5. Clarke-Pearson DL, Soper JT, Berchuck A, Rodriguez G, Dodge R, Soisson A, Cliby W, Kohler M, Olt G. "Closed retroperitoneal suction drainage following selective lymphadenectomy: risks and benefits." Society of Gynecologic Oncologists, San Antonio TX, Mar 1992.
 6. Berchuck A, Kohler M, Clarke-Pearson DL, Soper JT, Marks JR, Bast RC Jr. "Overexpression and mutation of the p53 oncogene in endometrial adenocarcinoma." Society of Gynecologic Oncologists, San Antonio, TX, Mar 1992.
 7. Kohler M, Berchuck A, Jacobs I, Marks J, Kerns BJ, Iglehart JD, Clarke-Pearson DL, Bast RC Jr. "Detection of p53 mutation and overexpression in paraffin-embedded ovarian cancers." Society of Gynecologic Oncologists, San Antonio, TX, Mar 1992.
 8. Berchuck A, and Kohler M. "Expression of tumor suppressor genes in gynecologic cancers." Mini-symposia on Oncogenes and Oncology. Society for Gynecologic Investigation, San Antonio TX, Mar 1992.
 9. Kohler MF, Jacobs IJ, Berchuck A, Wiseman R, Marks J, Humphrey P, Ponder BJ, Bast RC, Jr. "Clonal origin of ovarian cancer: analysis by loss of heterozygosity, p53 mutation and X-chromosome inactivation." Society of Gynecologic Oncologists, Palm Desert, CA, Mar 1993.
 10. Berchuck A, Kohler MF, Soper JT, Clarke-Pearson DL, Nishii H, Sasaki H, Bast RC, Boyd J. "Mutational analysis of the K-ras and p53 genes in endometrial hyperplasias." Society of Gynecologic Oncologists, Palm Desert, CA, Mar 1993.
 11. Kohler MF, Berkholz A, Elbendary A, Boyd J, Bast RC Jr, Berchuck A. "Molecular genetic analysis of the estrogen receptor gene in endometrial carcinoma." American Association of Cancer Research, San Francisco, CA, Apr 1994.
 12. Berchuck A, Kohler MF, Carney P, Dodge R, Soper JT, Rodriguez GC, Robboy G, Clarke-Pearson DL. "Racial disparity in survival and p53 overexpression in advanced endometrial adenocarcinoma." Society of Gynecologic Oncologists, New Orleans, LA, Feb 1996.
 13. Gillette CN, Burger RA, Kohler MF, Monk BJ, Seewaldt VL, Greer BE, Manetta A. "Paclitaxel-associated intestinal complications in patients with ovarian cancer". Western Association of Gynecologist Oncologist, San Diego, CA, Jun 1996.

14. Brewster WP, Kurosaki TT, Anton-Culver H, Berman ML, DiSaia PJ, Manetta A, Kohler MF. "Participation of gynecologic oncologist in the primary surgical management of endometrial cancer in Orange County California 1985-1994: A population based study." Society of Gynecologic Oncologist, Phoenix, AZ, Mar 1997. (Plenary Session)
15. Gillette CN, Kurosaki T, McMeekin S, Burger R, Manetta A, Vasilev S, DiSaia PJ, Berman ML, Kohler MF. "Bowel resection during primary surgical debulking for epithelial ovarian carcinoma." Western Association for Gynecologic Oncologist 1997 Annual Meeting Jasper, Alberta, Canada Jun 1997
16. Tewari K, Cappuccini F, Asrat T and Kohler MF. "Cancer in pregnancy: Lessons learned from several unique cases." Residents' Paper Day, Annual Meeting, The Phillip J DiSaia Society, Orange, CA May 1997.
17. Tewari K, Cappuccini F, Rose GS, Kohler MF, Manetta A, Berman ML and DiSaia PJ. "Malignant ovarian germ cell tumors: Management and survival- A twenty year experience." Residents' Paper Day, Annual Meeting, The Philip J. DiSaia Society, Orange, CA, May 1998.
18. Tewari K, Cappuccini F, Brewster WR, Syed AMN, DiSaia PJ, Berman ML, Manetta A and Kohler MF. "Interstitial brachytherapy for vaginal vault recurrences of endometrial cancer." Annual Meeting, The Western Association of Gynecologic Oncologist, Napa, CA, June 1998.
19. Look KY, Blessing JA, Levenback C, Kohler MF, Chafe WE, Roman LD. "A phase II trial of CPT 11 in chemotherapy-naive patients with recurrent squamous carcinoma of the cervix: A Gynecology Oncology Group Study." Society of Gynecologic Oncologist, Orlando, FL, February 1998.